2026 MIDD Webinar Series | Diverse Clinical Applications of a General Mechanistic Model of Therapeutic IgG-based Interactions
Includes a Live Web Event on 09/23/2026 at 12:00 PM (EDT)
-
Register
- Non-member - $50
- Member - Free!
IVIG co-administration with monoclonal-antibodies/bispecifics is common across autoimmunity, immunodeficiencies, and transplantation. These therapies undergo FcRn-mediated recycling, raising potential for PK-PD interactions. Mechanistic IgG-disposition model utilized to investigate how IVIG dose/timing, and IgG dynamics influence IgG behavior and PK/PD outcomes. Model well-described total/endogenous-IgG kinetics across autoimmune/transplantation. It recapitulated reduced tesidolumab exposure with IVIG in transplantation, explaining associated PD alterations. Model examined IVIG supplementation in multiple-myeloma receiving teclistamab, and rituximab-IVIG co-therapy for transplant desensitization. Simulations revealed IVIG co-therapy alters mAb PK-PD depending on IVIG-regimen, IgG-pool and exposure-response-relationship of the mAb. Model provides mechanistic framework for MIDD and prospective management of IgG interactions.
The MIDD Webinar Series, coordinated by Yash Kapoor and Fulya Akpinar Singh, is a series of webinars focused on shaping the future of drug development and regulatory decision-making sponsored by the ISoP Education Committee. Topics range from MIDD approaches in regulatory submission to pharmacometrics topics that are at the core of model development.
Paridhi Gupta
Research Investigator, Clinical Pharmacology-Early Oncology Group
Bristol Myers Squibb
Dr. Paridhi Gupta is a Research Investigator in the Clinical Pharmacology–Early Oncology group at Bristol Myers Squibb. She earned her Ph.D. in Pharmaceutical Sciences with a specialization in Pharmacometrics from the University of Tennessee Health Science Center under the mentorship of Prof. Bernd Meibohm. Paridhi has completed internships at Merck, Bristol Myers Squibb, and Johnson & Johnson, gaining broad experience in leveraging modeling and simulation to support preclinical and clinical drug development.
Vivaswath Ayyar
R&D Innovation Director, Translational Medicine; Adjunct Asst Professor, Pharmaceutical Sciences
GSK, University of Buffalo
Dr. Vivaswath Ayyar is the R&D Innovation Director for Translational Medicine at GSK and Adjunct Assistant Professor of Pharmaceutical Sciences at the University at Buffalo. His work focuses on advancing innovative therapeutics through translational science and model-informed approaches, leveraging causal data analytics and mechanistic platform modeling to inform decision-making across the R&D stages for emerging modalities, including advanced biologics and nucleic acid medicines. Prior to GSK, he spent six years at Johnson & Johnson, where him and his team built and leveraged mechanistic and/or systems pharmacology models to inform the biologics and oligonucleotide portfolios across disease areas.
Key:
Complete
Next
Failed
Available
Locked